Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
JFC ! What is wrong with this asshole company ?
Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulat...
https://ih.advfn.com/p.php?pid=nmona&article=77418409
EMC—GLTA!
LOL , I'll get on that PDQ , Ok ?
Emblems partner Cannatabs, is a subsidiary to MCL, Medical Cannabis Ltd.
MCL who is a subsidiary to QBL, will make a announcement on monday.
This will gain QBL-stock, since MCL is not listed themself. Trade halt will be lifted, once the secret announcement is made to market.
Here you have the possibility to take advantage on facts and info from QBL.
Like the QBL on ASX website chapter, who can provide verified facts; here is regulated on-line stockbrokers suggestion, no games info and a good sum up. Contact information to the QBL Investor service, who are correct. https://www.queenslandbauxite.com/
Emblem Announces 2017 Financial Results
2017 Highlights
Generated $2.69 million in revenues and reported gross profit of $490,000 during 2017
Granted licence to sell cannabis oils by Health Canada
Won Top Licensed Producer Customer Service Award at the 2017 Canadian Cannabis Awards
Registered approximately 2,500 new patients during 2017, an increase of 1250% from 2016
Raised a total of $44.7 million in gross proceeds from equity and debt financings
Appointed Nick Dean as Emblem’s Chief Executive Officer and President
Entered into an agreement with Canntab Therapeutics Limited (“Canntab”) to collaborate on the patent-pending oral sustained-release formulation for cannabinoids
Entered into a licensing agreement with Dosecann to collaborate on the development of a cannabis-oil spray dosage form, that will be followed by the development of dose-controlled vaporizers
Substantially completed Phase 2 expansion of the Company’s current facility expansion plan, providing an additional 5,200 square feet of grow space
Commenced construction of 30,000 square foot Phase 3 expansion which will accommodate a GMP extraction facility, laboratory and pharmaceutical production facility
Purchased 80 acres of land in Paris Ontario for cultivation expansion and product development purposes
Current 2018 Highlights to Date:
Generated record revenues of $1.2 million in the first quarter of 2018
Increased patient count to approximately 3,300 patients
Signed a key supplier agreement to become a medical cannabis supplier to Shoppers Drug Mart Inc.
Invested in Fire & Flower Inc. and entered into 3-year preferred supplier agreement
Continued to build a world-class leadership team with several key additions
Raised $53.8 million in gross proceeds from equity and debt financings
Nick Dean, Chief Executive Officer and President of Emblem commented, “2017 marked a transformational year for Emblem, as it achieved many milestones against product development (oils license received in Q4) and cultivation expansion. We are incredibly encouraged by the growth achieved through our patient acquisition efforts, the strategic partnerships formed with both Dosecann and Canntab, which position Emblem as a leader in product innovation, and the professional leadership team we began to assemble. The revenue and gross profit achieved in 2017 is a testament that Emblem is building a company focused on achieving fundamental business objectives that will drive long-term value for our shareholders. With the foundation firmly in place across product innovation, brand relevance, and access to end-user, our management team and the board of directors are encouraged with the prospects to significantly improve our revenue and margin profile as we enter 2018.”
https://ih.advfn.com/p.php?pid=nmona&article=77322451
EMC—GLTA!
The Cannatab MMJ SUITS of PRODUCTS, are getting closer to market sales.
According to latest say about this, the first batch will come to Australia in late may, if all goes as planned. The QBL subsidiary MCL are preparing for the first sales to take place as we speak.
See QBL-board and website;https://www.queenslandbauxite.com/
Considering the low valuation of QBL shares today, it can be a strong leverage once the medicals reach market for there first sales.
When's the extended release tablet release date?
CANNATAB and EMBLEM = True ! Liccensing agreement between the 2 companies looks very interesting - and CannaTab is about to lounge there Products
Read more; http://canntab.ca/
Cannatab is a subsidiary to QBL - check out the momentum now !
Here we go...
Emblem Continues to Bolster Professional Leadership Team with Three Strategic Hires to Grow Market Share
https://ih.advfn.com/p.php?pid=nmona&article=77183178
EMC—GLTA!
Globe says TD approves narrow selection of pot stocks
2018-04-13 07:47 ET - In the News
See In the News (C-TD) Toronto-Dominion Bank
The Globe and Mail reports in its Friday edition that TD Bank is plugging a pair of cannabis juniors. In a Globe special, Brenda Bouw writes that TD gave clearance for its investment advisers to recommend TSX Venture Exchange-listed Emblem and Emerald Health Therapeutics, in part because they are not involved in the legally murky U.S. cannabis market. Advisers at TD Wealth Private Investment Advice also received approval to recommend a third stock, Canopy Growth, the largest publicly traded producer. At the same time, the bank has instructed advisers not to recommend dozens of marijuana stocks and the four Canadian-listed cannabis ETFs by adding them to its list of non-approved securities. Cannabis stocks have plunged in recent weeks, following a runup in December and January. Shares of Toronto-based Emblem -- which has a production facility in Paris, Ont., and recently signed supplier agreements with Shoppers Drug Mart and retail brand Fire & Flower -- have slumped by about 60 per cent from its high of $3.35 on April 11, 2017. Victoria-based Emerald, which has a retail collaboration with Namaste Technologies, hit a high of $9.68 on Jan. 23 and has since fallen by about 58 per cent to around $4.10.
© 2018 Canjex Publishing Ltd. All rights reserved.
Absolutely spot on... Thanks for the charts! Happy to see this back above 1.50 today. I've always thought that this one will surprise us with a proper "unveiling" someday, as it hasn't followed the ebb and flow of the "rec plays" quite the same way and has stayed true to its brand.... Hoping for something sexy on the pharma side....time-release delivery? Fentanyl-esque MJ patches? I have messages IR and their Social Media team regularly....they need to throw us a bone here ! :)
GLTYA
Can it be??
Ontario Cannabis Store locations announced in Toronto, Guelph, Kingston and Thunder Bay
https://www.google.ca/amp/s/globalnews.ca/news/4138472/ontarios-first-four-marijuana-stores-announced/amp/
EMC
GLTA!
Emblem Signs Key Supplier Agreement with Shoppers Drug Mart
https://ih.advfn.com/p.php?pid=nmona&article=77066241
EMC—GLTA!
Emblem to supply medical pot to Shoppers Drug Mart
2018-03-29 08:09 ET - News Release
Ms. Ali Mahdavi reports
EMBLEM SIGNS KEY SUPPLIER AGREEMENT WITH SHOPPERS DRUG MART
Emblem Corp. has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart.
Subject to Health Canada's approval of Shoppers Drug Mart's application to be a licensed producer, under the terms of the agreement the Company will supply Shoppers Drug Mart with Emblem branded medical cannabis products. It is expected the products will be sold online, as Canadian regulations currently restrict the sale of medical cannabis in retail pharmacies.
Nick Dean, CEO of Emblem Corp., says the deal is an important milestone for Emblem. "From the very beginning we've been very focused on being a leader in the medical cannabis space, not only from the production side, but also when it comes to physician and patient education," says Dean. "Today's deal with Shoppers Drug Mart helps to solidify that and positions us well to be a world leader of cannabis for medical purposes."
About Emblem
Emblem Corp., through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals {A } cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
Best , most direct article I have read ! That truly sums up my attitude as well .
Oops that was wrong 1...
https://equity.guru/2018/03/28/emblem-cannabis-emc-v-ever-loving-hell-going/
they will go down to cash in bank and keep falling!!--tmonkey
Lol I hear ya... just spoke to him today and gave home some pointers. We shall see.
doesnt seem to matter with this one!!---when the sector runs this lags-and on a downturn this leads the way!!---and the new guys--ha!--tmonkey
The price makes no sense given the amount of money they have on hand, that they are licensed and that the phase two grow is almost up and running.
to think of the plays i missed while hoping for emc---mind blower for sure-DOWN TO 1.30 TODAY!!--i have cut out the cancer!!-now watch the buyout!--so far my avg for the NEW cron shares is under 9 can$---and may come down more next week-----tmonkey
I feel your pain , have thrown in towel on this turkey . Keeping my worthless shares as a reminder . Hear you about Cronos , even APH has come so far down , blows my mind .
took my loss here at 1.41-2-the last 2 days-and am getting back into cronos---some yesterday-some today----and daily to the bottom??---enough was enough here---i was a believer here but out now and wont look back!!!--------my only ticker is cronos now-----and ill not let go until the cows come home!.------------tmonkey
Liberal plan to legalize pot survives Senate vote
https://globalnews.ca/news/4100321/marijuana-legalization-bill-c45-passes-senate/
EMC—GLTA!
Here and hoping
Simone mist Beach Looking emblemtalk!!! .....tmonkey
Simone mist Beach Looking emblemtalk!!! .....tmonkey
What buyout do you speak of ? Check out the link https://news.lift.co/billion-dollar-cannabis-brand-medmen-coming-canada-via-cronos/?utm_source=ActiveCampaign&utm_medium=email&utm_content=Who+s+hiring+in+the+cannabis+industry%3F+Plus+-+our+newsletter+has+a+new+look&utm_campaign=Mar22WeeklyNRM-WhosHiring
fool me once .... . I am still here , but more skeptical .
They start info finally!!! Buyout 2++++ tmonkey
Emblem Corp. Issues President’s Letter to Shareholders
Emblem Corp. (TSXV:EMC) (EMC.WT) ("Emblem" or the "Corporation") provides a Letter to its Shareholders as follows:
Spring is upon us, and Emblem is ready to bloom.
Having just completed my first quarter as your new President and CEO of Emblem Corp., I would like to start by thanking the many groups who have made this exciting evolution of our company possible. The incredible support of our shareholder base and the significant efforts of our world-class management team have allowed us to quickly pivot our approach. This strategy strengthens our current position as a leading medical cannabis company, while creating a brand-leading division launch within the burgeoning adult-use market, slated to begin in Q3 2018.
With the two financing transactions Emblem successfully completed in the last 120 days our balance sheet is incredibly strong, with close to $85M available to support our growth plans. This financial strength allows us to complete construction of two, state-of-the-art cultivation and manufacturing facilities in Paris, ON, as well as seek out opportunities for further cultivation expansion. In addition, we will be making strategic investments in R&D, clinical research, marketing and promotion, product development and licensing. Each of these endeavors collectively allows Emblem to maintain its leadership position within the medical side, as well as poises us for a unique and competitive advantage in the adult-use space. Our team has been very active in pursuing these opportunities and we look forward to sharing some exciting announcements in the coming weeks.
The focus over the last 120-days has been that of assembling a world-class executive leadership team. I’m pleased to announce that we’ve made a number of significant hires across our finance, marketing and operations groups that will all play critical roles in propelling Emblem to the next level. We have restructured our organization around our three key disciplines: Medical under the continued leadership of John Stewart, Operations under the leadership of Danny Saperia, and Adult-use under the leadership of our new Chief Marketing Officer (to be announced).
Emblem is making stellar progress with two key construction projects in Paris, ON. Targeted for completion in late Q3 is our 30,000 sq.ft. integrated building that includes a GMP certified, state-of-the-art formulation and analytical laboratory. This will greatly increase space available for extraction, analytical, cannabis storage, R&D and formulation production activities. Our analytical laboratory will escalate its scope of activities, reducing reliance on external laboratories and expediting analytical turnaround time to allow for more efficient operations, while significantly reducing the company’s overall costs for analytical services.
We are also making improvements to our existing “closed-box” cultivation facility, with retro-fits to three grow rooms nearly complete in order to provide greater environmental control for our production team. In addition, we are assessing GMP certification for the facility, which would allow us to internationally export dried flower in addition to derivative products. International expansion is a key focus for Emblem’s growth strategy, and we have signed an LOI with a German pharmacy group to supply dried flower to Germany and the EU, subject to GMP compliance.
We have appointed Ellis Don as the construction manager of our purpose-built 170,000 sq. ft. greenhouse, with construction slated to begin within four to six weeks, contingent on site-plan approval from the County of Brant. After the planned completion date of Q1 2019, this new greenhouse is expected to increase our annual capacity by an additional 15,000 kgs, bringing our total funded capacity to 17,000 kgs.
Our Medical division entered 2018 with four different cannabis oils and a production capacity to meet the anticipated market demand for these oils, while at the same time developing additional oils with different cannabinoid profiles. A second objective is to bring oral metered dose spray formulations and oil-filled capsules to market in Q3, while simultaneously advancing the development of additional novel dosage forms of cannabinoids – in particular the sustained-release formulations in partnership with Canntab.
In anticipation of the commercial availability of the cannabis oils, a seven-person “pharma” salesforce was established by our GrowWise division in late 2017. These individuals are now presenting information on the oils to independent physicians with appropriate patient rosters, as well as to physicians in cannabis clinics. Over the first three months that the cannabis oils have been on the market, their uptake has shown rapid growth - to the point that they now represent approximately 30% of the company’s monthly sales total. As a result, we are optimistic about both the immediate and future impacts the cannabis oils and other dosage forms will have on sales. Health Canada’s latest market data continues to reveal that dried flower sales growth has been minimal over the last two quarters, while oil sales have increased by approximately 35%. The availability of Emblem’s proprietary cannabis oils also represents the appropriate time to begin clinical research projects, demonstrating their efficacy in the management of various conditions. We anticipate these trials to be initiated in Q3.
Emblem is also in discussion with potential partners for development of transdermal cannabis patches, topical cannabis creams, lotions and/or oils, vape pens and metered-dose inhalers. Other potential partnerships include companies with the capability to collaborate on the development of cannabis-based oral thin strips and soft-gel cannabis capsules.
Our Adult-use division has made great progress in an incredibly short period of time. We will be entering the market with two specific brands, each targeting a distinct segment; 1. Health and Wellness Enthusiasts, and 2. Casual Users. To bring these brands to market, we have recently hired the services of a multiple award-winning advertising agency, No Fixed Address (NFA), as Emblem’s Agency of Record. We will enter the market well in advance of legalization to start a groundswell of demand and anticipation for our products once they are available on shelf. The scope of services NFA will provide include:
Create and execute a national PR strategy to help Emblem Corp. launch our adult-use recreational brand ahead of the proposed date for legalization.
Create and execute a series of experiential/activation campaigns with Emblem’s adult-use recreational brands.
Ultimately, create enough awareness that Emblem’s recreational brands will be the first products that consumers try when the legal market comes into effect.
At the same time, we are actively pursuing supplier agreements with the highest growth provinces for our adult-use products and brands. We are confident about the direction of these discussions and anticipate that our products and brands will achieve premium positioning within stores.
Additionally, we are pursuing supplier agreements with private retail (both recreational and pharmacy) and strategic partnerships with value-add products, recognizing that the adult-use market will also be comprised of dosage forms and products other than dried flower (e.g. vape pens, concentrates, edibles).
On behalf of the Emblem leadership team, we appreciate your continued confidence and support. We have a busy, yet exciting year ahead of us. And we are unwaveringly committed to making Emblem one of Canada’s top-performing LP’s for all of our shareholders.
Nick Dean, President & CEO
Emblem Corp.
For further information contact:
Ali Mahdavi
Emblem Corp.
(416) 962-3300
alimahdavi@emblemcorp.com
https://ih.advfn.com/p.php?pid=nmona&article=76993150
EMC—-GLTA!
Emblem Selects No Fixed Address (NFA) as its Agency of Record
Emblem Corp. (TSXV:EMC) (TSXV:EMC.WT) ("Emblem" or the "Corporation") is pleased to announce that it has selected No Fixed Address (“NFA”) as its agency of record, following a Request for Proposal process that included five agencies. Through the partnership, NFA and Emblem will work together on marketing communication needs and brand initiatives ahead of legalization, with in-market activities set to begin in early Q2.
Further details on the selection were published in Strategy Online:
http://strategyonline.ca/2018/03/19/emblem-picks-no-fixed-address-as-aor/
About Emblem
Emblem Corp. is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol “EMC” on the TSX Venture Exchange.
About No Fixed Address
NFA is a full-service creative and digital agency designed to provide clients with the experience of a roster of proven talent and an entrepreneurial underpinning to it all. We approach every client challenge with an open mind allowing us to provide a tailored solution that puts your business first. We have no fixed agenda other than to share our true passion for the business that we’re in and to make our clients successful.
We are fortunate to work with a range of clients including Questrade, MLSE, J.P. Wiser's, Disney, Canadian Centre for Child Protection, Sunnybrook Health Sciences Centre, RioCan, and Mattamy Homes.
NFA is proud to be ranked as the #3 Digital Agency in Canada in 2017 by Strategy Magazine.
https://ih.advfn.com/p.php?pid=nmona&article=76981087
EMC—-GLTA!
As bad as yesterdays performance was , it was better than todays . POS
Positive outlook ! Volume is still horrible across sector , this dog is always slow , but so are ACB and WEED .
just think of them buying this hound for chump change---but a good premium to market price and we get mnj shares-----bet they are looking right now!!lol---------tmonkey
Awesome to see , they earned it !
if you check out cronos today be sure you are sitting down!!! cronos monkey--
For the uneducated like myself , what does the chart tell you ?
Great call on Cronos , you nailed it .
I see that and am baffled . Nothing surprises me about Emblem , however .
the others i follow were all on the low side also!!dont know why??----tmonkey
I had to look twice at todays volume , was it a holiday ? Holy shit , scary low .
the warrents are a get rich quick scheme if the stock moves up fast----there was that run where if people got out they made$$-----but greed probably made people double down for a real rude kick in the ??-------i dont buy em either!!---------tmonkey
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
646
|
Created
|
12/07/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |